Small molecule · developed by Novartis
Triclabendazole is an anthelmintic agent against Fasciola species, given as an oral tablet. It is used in the treatment of fascioliasis, a parasitic infection of the liver caused by liver flukes.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 4, 2026). Read the full label for the exact wording, limitations and safety information.
Fascioliasis
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →